March 24, 2021
DETROIT, March 25, 2021 – The Gilbert Family Foundation (GFF) and Rocket Community Fund today announced an unprecedented and transformational $500 million philanthropic investment over the next ten years, to be accomplished through strategic contributions to community organizations that will build economic opportunity in Detroit neighborhoods. The Gilbert Family Foundation will contribute $350 million, and […]
June 12, 2020
On April 10, 2020, the FDA approved the first drug that was ever developed for neurofibromatosis type 1 (NF1). Selumetinib (aka AstraZeneca’s Koselugo) has been approved to treat symptomatic and inoperative NF1-associated plexiform neurofibromas and is currently in the midst of clinical trials to evaluate the possible benefits to other NF1-associated tumors.
December 24, 2020
GFF's Gene Therapy Initiative seeks to explore and develop gene-targeting therapeutic strategies for neurofibromatosis type 1 (NF1) that address the underlying cause of the disease. Targeting the mutated gene itself could yield a more effective, comprehensive response for a greater range of patients.